Glenmark Pharmaceuticals Limited (GLENMARK) Financial Statements

5 Followers

Glenmark Pharmaceuticals Limited Financial Overview

Glenmark Pharmaceuticals Limited's market cap is currently ₹607.93B. The company's EPS TTM is ₹35.78; its P/E ratio is 44.64; and it has a dividend yield of 0.24%. Glenmark Pharmaceuticals Limited is scheduled to report earnings on May 29, 2026, and the estimated EPS forecast is ₹―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22
Income Statement
Total Revenue	₹ 169.83B	₹ 133.63B	₹ 126.45B	₹ 116.56B	₹ 123.05B
Gross Profit	₹ 80.84B	₹ 88.38B	₹ 80.66B	₹ 72.45B	₹ 77.57B
Operating Income	₹ 39.99B	₹ 41.84B	₹ 33.94B	₹ 28.11B	₹ 35.60B
EBITDA	₹ 27.67B	₹ 21.68B	₹ 18.30B	₹ 14.29B	₹ 19.12B
Net Income	₹ 13.62B	₹ 10.47B	₹ -15.02B	₹ 2.97B	₹ 9.42B
Balance Sheet
Cash & Short-Term Investments	₹ 14.01B	₹ 17.12B	₹ 16.64B	₹ 11.73B	₹ 14.43B
Total Assets	₹ 199.08B	₹ 160.50B	₹ 143.59B	₹ 193.72B	₹ 170.83B
Total Debt	₹ 5.94B	₹ 24.73B	₹ 12.31B	₹ 46.08B	₹ 39.62B
Net Debt	₹ -5.83B	₹ 7.97B	₹ -4.27B	₹ 34.49B	₹ 25.51B
Total Liabilities	₹ 93.96B	₹ 72.00B	₹ 65.11B	₹ 95.32B	₹ 76.45B
Stockholders' Equity	₹ 105.12B	₹ 88.49B	₹ 78.48B	₹ 94.74B	₹ 90.87B
Cash Flow
Free Cash Flow	₹ 19.41B	₹ -15.77B	₹ -11.64B	₹ 176.29M	₹ 3.19B
Operating Cash Flow	₹ 32.99B	₹ -8.28B	₹ -2.65B	₹ 6.25B	₹ 11.09B
Investing Cash Flow	₹ -13.25B	₹ 20.94M	₹ 45.44B	₹ -5.28B	₹ -3.33B
Financing Cash Flow	₹ -25.21B	₹ 7.87B	₹ -39.06B	₹ -774.56M	₹ -5.20B

Currency in INR

Glenmark Pharmaceuticals Limited Earnings and Revenue History

Income Statement >

Glenmark Pharmaceuticals Limited Debt to Assets

Balance Sheet >

Glenmark Pharmaceuticals Limited Cash Flow

Cash Flow >

Glenmark Pharmaceuticals Limited Forecast EPS vs Actual EPS

Earnings >